Combination Therapy of 15-Epi-Lipoxin A4 With Antibiotics Protects Mice From Escherichia coli–Induced Sepsis*
- 1 April 2014
- journal article
- online laboratory-investigations
- Published by Wolters Kluwer Health in Critical Care Medicine
- Vol. 42 (4) , e288-e295
Abstract
Objectives: Inflammation occurs along with infection during sepsis. 15-Epi-lipoxin A4 has protective and resolving effects in experimental models of infection. In this study, we examined the effects of 15-epi-lipoxin A4 combined with antibiotics on Escherichia coli–induced peritonitis. Design: Prospective experimental study. Setting: University research laboratory. Subjects: Male C57BL/6 mice. Interventions: Mice were injected with E. coli to induce peritonitis and were given either 15-epi-lipoxin A4 (1 μg/mouse) or placebo (saline) with antibiotics (ceftazidime). The effects of 15-epi-lipoxin A4 on peritoneal cell populations, bacterial burden, and cytokine production were assessed. Survival rates were observed for up to 7 days. In addition, we examined the effects of 15-epi-lipoxin A4 on peritoneal macrophages stimulated with lipopolysaccharide, CpG DNA, or live E. coli. Measurements and Main Results: Treatment with 15-epi-lipoxin A4 significantly reduced the number of neutrophils in the peritoneum, inhibited production of cytokines and chemokines, and decreased bacterial load in the serum. Combined treatment of 15-epi-lipoxin A4 with antibiotics significantly improved survival in E. coli–infected mice. 15-Epi-lipoxin A4 also attenuated the production of interleukin-6 and tumor necrosis factor-α by lipopolysaccharide- or CpG DNA-stimulated peritoneal macrophages. Furthermore, 15-epi-lipoxin A4 combined with antibiotics synergistically reduced the production of interleukin-6 and tumor necrosis factor-α by peritoneal macrophages stimulated with live E. coli. Conclusions: 15-Epi-lipoxin A4 combined with antibiotics attenuated systemic inflammation, inhibited bacteria dissemination, and improved survival in E. coli–infected mice. The reduced production of interleukin-6 and tumor necrosis factor-α by peritoneal macrophages suggested that 15-epi-lipoxin A4 blocked the initial proinflammatory response. Taken together, these data suggested that 15-epi-lipoxin A4 combined with antibiotics was beneficial in regulating the proinflammatory response in sepsis without exacerbating infection.Keywords
This publication has 41 references indexed in Scilit:
- Hospitalizations, costs, and outcomes of severe sepsis in the United States 2003 to 2007Critical Care Medicine, 2012
- The Surviving Sepsis Campaign: Results of an international guideline-based performance improvement program targeting severe sepsis*Critical Care Medicine, 2010
- The Anti-Inflammatory and Proresolving Mediator Resolvin E1 Protects Mice from Bacterial Pneumonia and Acute Lung InjuryThe Journal of Immunology, 2009
- Resolvin D2 is a potent regulator of leukocytes and controls microbial sepsisNature, 2009
- Corticosteroids in the Treatment of Severe Sepsis and Septic Shock in AdultsJAMA, 2009
- Endogenous pro‐resolving and anti‐inflammatory lipid mediators: a new pharmacologic genusBritish Journal of Pharmacology, 2008
- Hydrocortisone Therapy for Patients with Septic ShockNew England Journal of Medicine, 2008
- Molecular Circuits of Resolution: Formation and Actions of Resolvins and ProtectinsThe Journal of Immunology, 2005
- Has the mortality of septic shock changed with time?Critical Care Medicine, 1998
- Sir Isaac Newton, sepsis, SIRS, and CARSCritical Care Medicine, 1996